Evidence map›Paper›PMID 40445205›Full record

ArticleEpilepsia2025

The UMPIRE study: A first-in-human multicenter trial of bilateral subscalp monitoring for epileptic seizure detection.

Amy J Halliday, Lisa Gillinder, Alan Lai, Udaya Seneviratne, Holly Fontenot, Tracy Cameron, Karen McLean, Andrew Niemiec, Ramya Raghupathi, Taneeta M Ganguly and 19 more

2 registry-linked trialsAbstract readMulticenter Study
In one paragraph

Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07110337 narecruitingnot on this map

A Prospective Study to Evaluate the Use of the Minder Device to Aid in Developing a Treatment Plan After Inconclusive Prolonged EEG in Patients With Epilepsy

TypeinterventionalSponsorEpiminder America, Inc.Ran2025 to 2027Enrolled210ConditionsEpilepsy, Epilepsy (Treatment Refractory)ArmsReceipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
NCT07110454 recruitingnot on this mapstarted 2026, after this paper: background citation

A Prospective Long-Term Follow-Up Study to Evaluate the Use of the Minder Device to Aid in Treatment After Actionable Event Identification in Patients Diagnosed With Epilepsy.

TypeobservationalSponsorEpiminder America, Inc.Ran2026 to 2029Enrolled210ConditionsEpilepsy, Epilepsy (Treatment Refractory)ArmsPrevious receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Holistic management of epilepsy in adults with intellectual development disorders.Epileptic disorders : international epilepsy journal with videotape · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Amy J HallidayDepartment of Clinical Neurosciences, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Lisa GillinderSchool of Medicine, University of Queensland, St Lucia, Queensland, Australia.
Alan LaiDepartment of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia.
Udaya SeneviratneDepartment of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia.
Holly FontenotEpiminder, Melbourne, Victoria, Australia.
Tracy CameronEpiminder, Melbourne, Victoria, Australia.
Karen McLeanEpiminder, Melbourne, Victoria, Australia.
Andrew NiemiecEpiminder, Melbourne, Victoria, Australia.
Ramya RaghupathiPenn Neuroscience Center-Neurology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0009-0007-5080-5084
Taneeta M GangulyPenn Neuroscience Center-Neurology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Colin EllisPenn Neuroscience Center-Neurology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Erin C ConradPenn Neuroscience Center-Neurology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Robert BriggsDepartment of Surgery, Otolaryngology, Royal Victorian Eye and Ear Hospital, University of Melbourne, East Melbourne, Victoria, Australia.
Kristian BullussDepartment of Neurosurgery, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Patrick KwanNeurology Department, Alfred Health, Melbourne, Victoria, Australia.
Piero PeruccaDepartment of Medicine, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-7855-7066
Terence J O'BrienNeurology Department, Alfred Health, Melbourne, Victoria, Australia.
Aileen McGonigalSchool of Medicine, University of Queensland, St Lucia, Queensland, Australia.ORCID https://orcid.org/0000-0001-6775-5318
Matthew GutmanDepartment of Neurosciences, Central Clinical School, Alfred Hospital, Monash University, Melbourne, Victoria, Australia.
Jason PapacostasDepartment of Neurosurgery, Mater Hospital, Brisbane, Queensland, Australia.
Michael W K FongWestmead Comprehensive Epilepsy Centre, University of Sydney, Sydney, New South Wales, Australia.
Andrew LeeFlinders Medical Centre, Adelaide, South Australia, Australia.
Douglas E CromptonDepartment of Neurology, Northern Health, Epping, Victoria, Australia.
Joshua LaingNeurology Department, Alfred Health, Melbourne, Victoria, Australia.
Manori WijayathDepartment of Neurology, Westmead Hospital, Westmead, New South Wales, Australia.
Andrew P MorokoffDepartment of Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.
Michael MurphyDepartment of Surgery, University of Melbourne, Parkville, Victoria, Australia.
Wendyl J D'SouzaDepartment of Clinical Neurosciences, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Mark J CookDepartment of Clinical Neurosciences, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.

Funding

EpiminderVictorian Government Department of Jobs, Skills, Industry and Regions
6 · The paper itself

Abstract

objectivePatient self-report is known to be an inaccurate reflection of true seizure frequency in persons with epilepsy. The current study aimed to assess the safety and performance of the Minder system, a bilateral subscalp electroencephalographic (EEG) acquisition system for continuous long-term EEG recording.

methodsThis prospective, multicenter first-in-human study enrolled adult patients with focal or generalized epilepsy and at least two seizures per month. The primary outcome was adverse events (AEs) in the first 6 months of implantation. Secondary analyses determined whether normal neurophysiological signals, interictal discharges, and seizures seen on scalp video-EEG monitoring were identifiable on subscalp recordings, and signals were rated for clarity on subscalp and two-channel scalp EEG recordings (1 = not recognizable, 5 = clear). Subscalp data were reviewed in relation to events reported in 6-month seizures diaries.

resultsTwenty-six subjects were implanted between November 2019 and July 2023. No serious device- or implant procedure-related AEs were reported. The most common device-related AEs were mild or moderate postsurgical pain, headache, or scalp pain/paresthesia (9/26, 35%). All sleep spindles, chewing artifacts, interictal discharges, and electrographic seizures observed on scalp recordings (25 seizures from eight patients) were identified on subscalp recordings and given higher clarity ratings compared to two-channel scalp recordings (median seizure clarity rating was 3 for both scalp and subscalp EEG, range = 1-5, p = .0025). Subscalp recordings captured seizures from diverse seizure focus locations, including frontal and mesial temporal seizure foci and hypothalamic hamartoma. Bilateral recording revealed clinically relevant findings not possible with unilateral recordings (6/26 patients, 23%). Findings of potential clinical utility were identified on manual review of 6-month recordings in most patients (23/26, 88%). SIGNIFICANCE: This study demonstrates the safety and performance of the Minder bilateral subscalp EEG acquisition system for long-term seizure monitoring in patients with epilepsy. Bilateral hemisphere coverage captured seizures in a diverse patient group and permitted lateralization of events.

Indexed as

ElectroencephalographyEpilepsySeizuresAdolescentAdultElectrodes, ImplantedFemaleHumansMaleMiddle AgedProspective StudiesYoung Adultambulatoryelectroencephalographyepilepsymonitoringsubscalp

Identifiers

PMID40445205
PMCPMC12455381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.